ALTSTATION.IO

Molina Healthcare, Inc. (MOH) Stock Analysis

By Nova Skye | AltStation.io | Updated February 07, 2026

Price

$129.31

Change

-26.88%

Market Cap

$7.01B

Avg Volume

1.6M

Company Overview

Molina Healthcare, Inc. (MOH) provides managed healthcare services focused on low-income families and individuals. They primarily operate through Medicaid and Medicare programs, as well as state insurance marketplaces. Their services cover a range of health management needs, making it easier for vulnerable populations to access necessary care. Founded in 1980, Molina is headquartered in Long Beach, California.

Molina is generally seen as a market leader in the Medicaid segment but operates in a competitive landscape that includes major players like Anthem, Centene, and UnitedHealth Group. Their edge comes from their specialized focus on underserved populations and a growing national footprint. However, competitive pressures are fierce, particularly as states increasingly move toward integrated care models that could challenge Molina’s traditional business.

Right now, Molina is in a growth phase. They’ve been expanding their services and geographic reach, particularly with recent acquisitions aimed at bolstering their Medicare offerings. Their strong performance in 2023 shows revenues up by 7%, with a focus on increasing their membership base. Key milestones include a successful launch of new health plans in several states, positioning them well for future opportunities in the increasingly important healthcare sector.

Key Financials

Market Cap

$7.01B

Revenue

$42.84B

EBITDA

$1.46B

Gross Margin

10.5%

Profit Margin

2.1%

Revenue Growth

11.6%

Total Cash

$8.45B

Total Debt

$3.85B

Free Cash Flow

-$186.38M

52-Week Price Performance Analysis

Price Statistics

P/E Ratio

7.97

Forward P/E

8.05

Beta

0.49

52-Week High

$359.97

52-Week Low

$125.00

EPS

$16.23

50-Day Avg

$171.74

200-Day Avg

$207.69

Price/Book

1.57

Technical Analysis

Molina Healthcare, Inc. (MOH) has shown a significant downward trend over the past 52 weeks, with a sharp decrease of 54%, suggesting considerable weakness in the stock. Key support is identified around the $50 level, where the price found stability earlier in the year, while resistance is seen near $65.4, which marks a previous high in January. The stock has experienced notable volatility, with clear price patterns such as descending peaks throughout mid-2022 and a brief recovery rally towards the end of that year. Recent momentum has slightly improved, particularly in the last few weeks, as the stock has climbed from near $110 to its current price of $129.31. This positions the current price roughly 25% above its 52-week low, indicating some recovery, but still significantly below the peak levels, which implies potential resistance challenges as it approaches previous highs.

Recent News and Developments

Here are the latest news and developments for Molina Healthcare, Inc

(MOH) stock in the past week, covering February 1-7, 2026:

Market Update

### Molina Healthcare Shares Plummet 33% Following Disappointing 2026 Earnings Guidance

Market Update

Molina Healthcare (MOH) experienced a significant stock decline of approximately 33% in after-hours trading on Thursday, February 5, 2026, after releasing its fourth-quarter financial results and a much lower-than-expected earnings forecast for 2026. The company projected 2026 adjusted earnings of at least $5.00 per share, falling considerably short of the consensus analyst estimate of $13.71. Add

Market Sentiment and Analyst Recommendations

Bull Case

MOH trades at a 7.97 P/E multiple, which is genuinely cheap for a company generating $42.84B in revenue with 11.6% growth. The balance sheet is solid with $8.45B in cash against $3.85B in debt, giving management flexibility to weather the current storm. The 33% crash already priced in massive pain, so the stock is oversold relative to what a normalized Medicaid operator should trade at. Medicaid enrollment remains large and sticky despite the chaos, and the company still has core dual eligible Medicare business that’s less volatile than MAPD. If MOH can stabilize margins and prove the new Medicaid contract performs as promised in 2027, the stock has clear upside to $180-200 from current levels. The analyst target of $186.06 implies 44% upside even after the recent bloodbath.

Bear Case

The 2026 earnings guidance of $5.00 per share versus consensus of $13.71 is a complete miss that destroys the bull thesis entirely. MAPD exit eliminates $1B in annual premiums and signals operational dysfunction in a major product line, not just market conditions. The new Medicaid contract is clearly a margin killer with a $2.50 per share headwind, and there’s no visibility yet on when that drag reverses. MOH’s 52-week range of $125-$359.97 shows how badly management’s prior guidance was off, which erodes credibility. The stock is down 54% over 52 weeks and only recently bounced to $129.31, so the recovery could be a dead cat bounce before further deterioration. Medicaid funding uncertainty and state-level policy changes remain constant threats that MOH can’t control.

What to Watch

Q1 2026 results in late April will be the first real test of whether the new Medicaid contract stabilizes or continues hemorrhaging. Monitor Medicaid enrollment trends state-by-state, particularly in MOH’s core markets, since any loss of covered lives directly impacts premiums. Watch for analyst downgrades over the next 2-3 weeks as firms reassess fair value below $186, which could trigger another leg down. Track the dual eligible Medicare enrollment numbers for 2027, since that’s now the company’s stated strategic focus and needs to show growth to offset MAPD exit. Look for management commentary on Medicaid contract margin trajectory and any guidance updates in Q1 earnings that indicate whether 2027 earnings will actually recover toward $12-13 per share or stay depressed. The $145-150 support level is critical; a break below signals the bear case is winning and 2026 guidance cuts could come again.

Analyst Consensus

HOLD

Based on 16 analyst opinions

Low Target

$145.00

Mean Target

$186.06

High Target

$311.00

Earnings and Financial Data

Sector

Healthcare

Industry

Healthcare Plans

Employees

18,000

Earnings & Dividends

Next Earnings

Apr 22, 2026

EPS (Trailing)

$16.23

Dividend Yield

None

Payout Ratio

Frequently Asked Questions

Is MOH a good stock to buy?

Molina Healthcare, Inc. (MOH) has a P/E ratio of 7.97, indicating it’s relatively undervalued compared to the broader market. However, analysts recommend a HOLD with a target price of $186.06, suggesting limited upside in the near term. This stock might be more suitable for risk-tolerant investors looking for sector-specific exposure.

What is MOH’s price target?

Analysts have set a target price for MOH at $186.06. Given the current price of $129.31, there’s potential for about a 44% upside, but be cautious; the stock needs to overcome its recent volatility.

Does MOH pay a dividend?

No, Molina Healthcare does not pay a dividend. The focus appears to be on reinvestment and growth rather than returning cash to shareholders.

What has been MOH’s 52-week performance?

MOH’s stock has traded between $125.00 and $359.97 over the past year. The significant drop from its 52-week high indicates increased volatility and potential concerns in the healthcare sector.

How does MOH’s valuation compare to its peers?

With a P/E of 7.97 and a forward P/E of 8.05, MOH appears cheaper than many competitors in the healthcare plans industry. This could present a buying opportunity if investors believe in a recovery, but the recommendation remains a cautious HOLD for now.

Related Stock Reports

Disclaimer: This report is for informational purposes only and does not constitute financial advice. The analysis and opinions expressed are those of AltStation.io and should not be relied upon as the sole basis for investment decisions. Always conduct your own research and consult with a qualified financial advisor before making investment decisions. Past performance does not guarantee future results. Updated February 07, 2026.